|
1
|
Uhlenhopp DJ, Then EO, Sunkara T and
Gaduputi V: Epidemiology of esophageal cancer: Update in global
trends, etiology and risk factors. Clin J Gastroenterol.
13:1010–1021. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Domper Arnal MJ, Ferrández Arenas Á and
Lanas Arbeloa Á: Esophageal cancer: Risk factors, screening and
endoscopic treatment in western and eastern countries. World J
Gastroenterol. 21:7933–7943. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao Q, Yu J and Meng X: A good start of
immunotherapy in esophageal cancer. Cancer Med. 8:4519–4526. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Borggreve AS, Kingma BF, Domrachev SA,
Koshkin MA, Ruurda JP, van Hillegersberg R, Takeda FR and Goense L:
Surgical treatment of esophageal cancer in the era of multimodality
management. Ann N Y Acad Sci. 1434:192–209. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Watanabe M, Otake R, Kozuki R, Toihata T,
Takahashi K, Okamura A and Imamura Y: Recent progress in
multidisciplinary treatment for patients with esophageal cancer.
Surg Today. 50:12–20. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li H, Fang W, Yu Z, Mao Y, Chen L, He J,
Rong T, Chen C, Chen H, Chen K, et al: Chinese expert consensus on
mediastinal lymph node dissection in esophagectomy for esophageal
cancer (2017 edition). J Thorac Dis. 10:2481–2489. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hirano H and Boku N: The current status of
multimodality treatment for unresectable locally advanced
esophageal squamous cell carcinoma. Asia Pac J Clin Oncol.
14:291–299. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park R, Williamson S, Kasi A and Saeed A:
Immune therapeutics in the treatment of advanced gastric and
esophageal cancer. Anticancer Res. 38:5569–5580. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khan S and Gerber DE: Autoimmunity,
checkpoint inhibitor therapy and immune-related adverse events: A
review. Semin Cancer Biol. 64:93–101. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang W, Wang P and Pang Q: Immune
checkpoint inhibitors for esophageal squamous cell carcinoma: A
narrative review. Ann Transl Med. 8:11932020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wolchok JD, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J,
Dummer R, et al: Long-term outcomes with nivolumab plus ipilimumab
or nivolumab alone versus ipilimumab in patients with advanced
melanoma. J Clin Oncol. 40:127–137. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rathmell WK, Rumble RB, Van Veldhuizen PJ,
Al-Ahmadie H, Emamekhoo H, Hauke RJ, Louie AV, Milowsky MI, Molina
AM, Rose TL, et al: Management of metastatic clear cell renal cell
carcinoma: ASCO guideline. J Clin Oncol. 40:2957–2995. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sheng J, Li H, Yu X, Yu S, Chen K, Pan G,
Xie M, Li N, Zhou Z and Fan Y: Efficacy of PD-1/PD-L1 inhibitors in
patients with non-small cell lung cancer and brain metastases: A
real-world retrospective study in China. Thorac Cancer.
12:3019–3031. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Awada A, Ahmad S, McKenzie ND and Holloway
RW: Immunotherapy in the treatment of platinum-resistant ovarian
cancer: Current perspectives. Onco Targets Ther. 15:853–866. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin SY, Yang CY, Liao BC, Ho CC, Liao WY,
Chen KY, Tsai TH, Hsu CL, Hsu WH, Su KY, et al: Tumor PD-L1
expression and clinical outcomes in advanced-stage non-small cell
lung cancer patients treated with nivolumab or pembrolizumab:
Real-world data in Taiwan. J Cancer. 9:1813–1820. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kojima T, Shah MA, Muro K, Francois E,
Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, et al:
Randomized phase III KEYNOTE-181 study of pembrolizumab versus
chemotherapy in advanced esophageal cancer. J Clin Oncol.
38:4138–4148. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T,
Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al: Safety and
efficacy of pembrolizumab monotherapy in patients with previously
treated advanced gastric and gastroesophageal junction cancer:
Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 4:e1800132018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chennamadhavuni A, Abushahin L, Jin N,
Presley CJ and Manne A: Risk factors and biomarkers for
immune-related adverse events: A practical guide to identifying
high-risk patients and rechallenging immune checkpoint inhibitors.
Front Immunol. 13:7796912022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cortellini A, Chiari R, Ricciuti B, Metro
G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R,
et al: Correlations between the immune-related adverse events
spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients.
Clin Lung Cancer. 20:237–247.e1. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ramos-Casals M, Brahmer JR, Callahan MK,
Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X,
Prat A and Suárez-Almazor ME: Immune-related adverse events of
checkpoint inhibitors. Nat Rev Dis Primers. 6:382020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu S, Lai R, Zhao Q, Zhao P, Zhao R and
Guo Z: Correlation between immune-related adverse events and
prognosis in hepatocellular carcinoma patients treated with immune
checkpoint inhibitors. Front Immunol. 12:7940992021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Toi Y, Sugawara S, Kawashima Y, Aiba T,
Kawana S, Saito R, Tsurumi K, Suzuki K, Shimizu H, Sugisaka J, et
al: Association of immune-related adverse events with clinical
benefit in patients with advanced non-small-cell lung cancer
treated with nivolumab. Oncologist. 23:1358–1365. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mischel AM and Rosielle DA: Eastern
cooperative oncology group performance status #434. J Palliat Med.
25:508–510. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
National Health Commission Of The People's
Republic Of China, . Chinese guidelines for diagnosis and treatment
of esophageal carcinoma 2018 (English version). Chin J Cancer Res.
31:223–258. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Suo A, Chan Y, Beaulieu C, Kong S, Cheung
WY, Monzon JG, Smylie M, Walker J, Morris D and Cheng T:
Anti-PD1-induced immune-related adverse events and survival
outcomes in advanced melanoma. Oncologist. 25:438–446. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vaddepally R, Doddamani R, Sodavarapu S,
Madam NR, Katkar R, Kutadi AP, Mathew N, Garje R and Chandra AB:
Review of immune-related adverse events (irAEs) in non-small-cell
lung cancer (NSCLC)-their incidence, management, multiorgan irAEs,
and rechallenge. Biomedicines. 10:7902022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ricciuti B, Genova C, De Giglio A,
Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi
F and Chiari R: Impact of immune-related adverse events on survival
in patients with advanced non-small cell lung cancer treated with
nivolumab: long-term outcomes from a multi-institutional analysis.
J Cancer Res Clin Oncol. 145:479–485. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kato K, Shah MA, Enzinger P, Bennouna J,
Shen L, Adenis A, Sun JM, Cho BC, Özgüroğlu M, Kojima T, et al:
KEYNOTE-590: Phase III study of first-line chemotherapy with or
without pembrolizumab for advanced esophageal cancer. Future Oncol.
15:1057–1066. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Puzanov I, Diab A, Abdallah K, Bingham CO
III, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR,
et al: Managing toxicities associated with immune checkpoint
inhibitors: Consensus recommendations from the society for
immunotherapy of cancer (SITC) toxicity management working group. J
Immunother Cancer. 5:952017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Okiyama N and Tanaka R: Immune-related
adverse events in various organs caused by immune checkpoint
inhibitors. Allergol Int. 71:169–178. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou X, Yao Z, Yang H, Liang N, Zhang X
and Zhang F: Are immune-related adverse events associated with the
efficacy of immune checkpoint inhibitors in patients with cancer? A
systematic review and meta-analysis. BMC Med. 18:872020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sangro B, Chan SL, Meyer T, Reig M,
El-Khoueiry A and Galle PR: Diagnosis and management of toxicities
of immune checkpoint inhibitors in hepatocellular carcinoma. J
Hepatol. 72:320–341. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weinmann SC and Pisetsky DS: Mechanisms of
immune-related adverse events during the treatment of cancer with
immune checkpoint inhibitors. Rheumatology (Oxford). 58 (Suppl
7):vii59–vii67. 2019. View Article : Google Scholar : PubMed/NCBI
|
